PT Kimia Farma Tbk ("Kimia Farma"), together with Dr. Cipto Mangunkusumo National General Hospital ("RSCM"), continues to strengthen its position as a pioneer in the development of stem cells and their derivatives. Stem cells work by repairing damage at the cellular and tissue level, thus offering the potential for long-term recovery. Currently, Kimia Farma and RSCM's stem cell therapy is used for treatment in orthopedics and traumatology, and will continue to expand to dermatology and neuromusculoskeletal care.
To expand the reach and ensure equitable access to stem cell therapy services, Kimia Farma and RSCM are offering stem cell therapy services with another hospital, Dr. Hasan Sadikin General Hospital ("RSHS") in Bandung. This was outlined in the signing of a Stem Cell Therapy Service Cooperation Agreement between Kimia Farma, RSCM, and RSHS on Monday, October 13, 2025.
Previously, Kimia Farma and RSCM have collaborated with several hospitals to expand stem cell therapy services, including Dr. Kariadi General Hospital in Semarang and Siti Fatimah General Hospital in Palembang. All partner hospitals that have collaborated provide superior services and are recognized as referral hospitals in their respective regions. This is expected to expand the benefits of stem cell therapy to communities in West Java, Central Java, and South Sumatra.
Djagad Prakasa Dwialam, President Director of Kimia Farma, expressed his pride in the support of these hospital partners, enabling the expansion of the stem cell collaboration between Kimia Farma and RSCM to various regions.
"We are proud that the stem cell development, initially initiated by Kimia Farma and RSCM, can now be expanded to regional areas to provide modern biotechnology-based treatments. This step is part of Kimia Farma's commitment to continuous health innovation to support national health security," said Djagad.
Djagad further explained that the stem cell product resulting from the collaboration between Kimia Farma, RSCM, and the Faculty of Medicine, University of Indonesia, meets applicable standards for quality, safety, and product quality.
"To maintain quality in every production process, the Kimia Farma and RSCM stem cell production facilities obtained a Good Manufacturing Practices (CPOB) certificate from the Food and Drug Monitoring Agency (BPOM) in 2024. This makes it the only stem cell production facility located in a hospital," said Djagad.
Meanwhile, RSCM President Director Dr. Supriyanto, Sp.B, FINACS, M.Kes., believes this collaboration can strengthen collaboration between RSCM, regional referral hospitals, and the national pharmaceutical industry to expand access and equitable distribution of stem cell therapy services for people across Indonesia.
"We believe that the development of stem cell therapy is not only an advancement in medical technology, but also offers new hope for patients with degenerative diseases. We view this collaboration as the first step towards the birth of more innovations and research-based healthcare networks in the country. We express our highest appreciation to PT Kimia Farma Tbk and Dr. Hasan Sadikin General Hospital, Bandung, for their synergy and trust. We hope this collaboration will provide broad benefits for the advancement of healthcare services in Indonesia," added Dr. Supriyanto.
In addition to developing stem cell therapy services, Kimia Farma and its hospital partners are also opening opportunities to develop research and conduct stem cell clinical trials through multicenter studies. This collaborative research and clinical trials are necessary to demonstrate the efficacy of stem cell products based on strong evidence.
Kimia Farma also strives to raise public awareness of the importance of research-based treatment innovation domestically. Expanding stem cell services at these three hospitals will strengthen Indonesia's position as one of the countries actively developing stem cell-based therapies in Southeast Asia. Kimia Farma and RSCM are committed to continuously improving quality, production capacity, and joint research to support national health resilience in the field of regenerative medicine.